Targeted Therapeutic Agents for Colorectal Cancer

被引:23
作者
Chee, Cheng E. [1 ]
Sinicrope, Frank A. [1 ,2 ]
机构
[1] Mayo Clin, Div Oncol, Rochester, MN 55905 USA
[2] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA
关键词
Colorectal cancer; Targeted therapy; VEGF; EGFR; GROWTH-FACTOR RECEPTOR; POSTOPERATIVE ADJUVANT THERAPY; FLUOROURACIL PLUS LEUCOVORIN; TYROSINE KINASE INHIBITOR; III COLON-CANCER; PHASE-III; 1ST-LINE TREATMENT; RANDOMIZED-TRIAL; MONOCLONAL-ANTIBODY; ORAL CAPECITABINE;
D O I
10.1016/j.gtc.2010.08.017
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The treatment of colorectal cancer (CRC) has evolved substantially during the past decade with the advent of molecular targeted therapies Inhibitors to the vascular endothelial growth factor and epidermal growth factor receptor (EGFR) pathways have been shown to enhance the efficacy of cytotoxic chemotherapy in patients with advanced CRC and anti-EGFR antibodies demonstrate modest activity as monotherapeutic agents These biologic agents have improved patient outcomes and survival and have been incorporated into routine clinical practice establishing a new standard of care Molecular markers have recently been adopted into clinical practice with the finding that the KRAS oncogene is a predictive biomarker for anti-EGFR therapy whereby the therapeutic benefit of anti-EGFR treatment is restricted to tumors with wild-type KRAS The use of molecular targeted agents has fewer yet more specific toxicities compared with conventional cytotoxic drugs and enables a more personalized approach to cancer therapy In contrast to the results for advanced CRC, targeted therapies have not shown a benefit in the adjuvant setting for patients with resected colon cancer The goal of this review is to provide an update on the medical management of CRC, with a focus on the use of targeted therapy
引用
收藏
页码:601 / +
页数:14
相关论文
共 80 条
[1]   Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): Results from NCCTG Intergroup Phase III Trial N0147 [J].
Alberts, S. R. ;
Sargent, D. J. ;
Smyrk, T. C. ;
Shields, A. F. ;
Chan, E. ;
Goldberg, R. M. ;
Gill, S. ;
Kahlenberg, M. S. ;
Thibodeau, S. N. ;
Nair, S. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
[2]  
Alberts Steven R, 2005, Clin Colorectal Cancer, V5, P211, DOI 10.3816/CCC.2005.n.033
[3]   Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer [J].
Allegra, Carmen J. ;
Yothers, Greg ;
O'Connell, Michael J. ;
Sharif, Saima ;
Colangelo, Linda H. ;
Lopa, Samia H. ;
Petrelli, Nicholas J. ;
Goldberg, Richard M. ;
Atkins, James N. ;
Seay, Thomas E. ;
Fehrenbacher, Louis ;
O'Reilly, Seamus ;
Chu, Luis ;
Azar, Catherine A. ;
Wolmark, Norman .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (20) :3385-3390
[4]   Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].
Amado, Rafael G. ;
Wolf, Michael ;
Peeters, Marc ;
Van Cutsem, Eric ;
Siena, Salvatore ;
Freeman, Daniel J. ;
Juan, Todd ;
Sikorski, Robert ;
Suggs, Sid ;
Radinsky, Robert ;
Patterson, Scott D. ;
Chang, David D. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634
[5]   Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].
Andre, T ;
Boni, C ;
Mounedji-Boudiaf, L ;
Navarro, M ;
Tabernero, J ;
Hickish, T ;
Topham, C ;
Zaninelli, M ;
Clingan, P ;
Bridgewater, J ;
Tabah-Fisch, I ;
de Gramont, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351
[6]   Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial [J].
Andre, Thierry ;
Boni, Corrado ;
Navarro, Matilde ;
Tabernero, Josep ;
Hickish, Tamas ;
Topham, Clare ;
Bonetti, Andrea ;
Clingan, Philip ;
Bridgewater, John ;
Rivera, Fernando ;
de Gramont, Aimery .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) :3109-3116
[7]  
Baselga J, 2001, EUR J CANCER, V37, pS16
[8]   KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience [J].
Bokemeyer, C. ;
Bondarenko, I. ;
Hartmann, J. T. ;
De Braud, F. G. ;
Volovat, C. ;
Nippgen, J. ;
Stroh, C. ;
Celik, I. ;
Koralewski, P. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[9]  
BOS JL, 1989, CANCER RES, V49, P4682
[10]  
Bos M, 1997, CLIN CANCER RES, V3, P2099